Trial Profile
Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 May 2016
Price :
$35
*
At a glance
- Drugs Perifosine (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yakult Honsha
- 29 Jun 2012 New trial record
- 28 Jun 2012 The first patient received treatment, according to an AEterna Zentaris media release.